SCHEMBL5850220

SCHEMBL5850220

CCCCc1nc(CC(=O)c2ccc(F)cc2)[nH]c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.48
RAB9A P51151 5/20 0.41
NPC1 O15118 3/20 0.41
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
MAPT P10636 4/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
SMPD3 Q9NY59 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5851298 0.86 RAB9A (0.44) HTR7RAB9ANPC1ALDH1A1MAPK1
SCHEMBL5850187 0.83 SMPD3 (0.37) RAB9ANPC1ALDH1A1KDM4EHPGD
Hydrochloric Acid SCHEMBL5851860 0.79 RAB9A (0.47) HTR7RAB9ANPC1ALDH1A1MAPK1
SCHEMBL5849981 0.78 MAPT (0.41) HTR7RAB9ANPC1ALDH1A1MAPK1
SCHEMBL28789385 0.77 ALDH1A1 (0.41) ALDH1A1HPGDSMPD3LMNA
SCHEMBL5850191 0.76 RAB9A (0.42) HTR7RAB9ANPC1ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL5850180 0.72 RAB9A (0.49) RAB9ANPC1ALDH1A1MAPK1KDM4E
SCHEMBL27819913 0.72 ALDH1A1 (0.41) ALDH1A1HPGDMAPTSMPD3
SCHEMBL28216514 0.72 ALDH1A1 (0.41) ALDH1A1HPGDMAPTSMPD3
SCHEMBL5851313 0.69 RAB9A (0.66) RAB9ANPC1ALDH1A1MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984646-B2 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALHCARE AG (DE) 2006-01-10 US disclosed
EP-1412353-B1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2005-03-02 EP disclosed
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALTHCARE AG (DE) 2004-11-04 US disclosed
EP-1412353-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS Bayer HealthCare AG (DE) 2004-04-28 EP disclosed
WO-2003008413-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors MAPK1, MAPK3, MAP3K1 HTR7 3238/4885RAB9A 1505/4885NPC1 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.